Amgen's Trading Volume Surges 74% to $1.015 Billion Ranking 134th in Market Activity

On April 3, 2025, Amgen's trading volume reached $1.015 billion, marking a 74.12% increase from the previous day, ranking 134th in the day's stock market activity. Amgen's stock price rose by 1.36%.

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease. This approval allows Amgen to expand UPLIZNA's reach, treating a rare condition that previously had no approved treatment options.

The U.S. list price for UPLIZNA is $140,248.50 per dose. After two initial loading doses, patients receive UPLIZNA infusions every six months. This approval represents a significant opportunity for Amgen to expand its market share in the rare disease treatment sector.

Analysts have noted that this FDA approval could potentially drive Amgen's stock price higher, as it opens up a new market for the company's innovative treatment. The expanded label approval for UPLIZNA is expected to enhance Amgen's financial performance and strengthen its position in the pharmaceutical industry.